Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Type

Guidance programme

Advice programme

Showing 11 to 20 of 38

TitleReference numberPublishedLast updated
Daratumumab monotherapy for treating relapsed and refractory multiple myelomaTA783
Freelite assays for diagnosing multiple myeloma and related conditions (terminated assessment)DG47
Daratumumab with bortezomib, melphalan and prednisone for untreated multiple myeloma (terminated appraisal)TA771
Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitableTA763
clonoSEQ for minimal residual disease assessment in multiple myeloma, acute lymphoblastic leukaemia and chronic lymphocytic leukaemiaMIB278
Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TA726
Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TA727
MMprofiler for prognostic risk classification in multiple myelomaMIB270
Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myelomaTA695
Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myelomaTA680

Results per page

  1. 10
  2. 25
  3. 50
  4. All